



Q2 2013 SALES

Lure, July 16, 2013 – Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like.

Sales (€ millions)	2013	2012	Change	Change at constant exchange rates	Change at constant exchange rates and consolidation scope (like for like)
Q1	75.5	77.0	-2.0%	-1.0%	-1.4%
Q2	70.0	69.8	+0.3%	+1.5%	+1.4%
H1	145.5	146.8	-0.9%	+0.2%	0.0%

First half 2013 sales amounted to €145.5 million, compared to €146.8 million in first half 2012. Like-for-like sales came in at €146.8 million, on a par with first half 2012.

In a contrasting market environment, core product sales enjoyed buoyant growth of 5.7%.

Sales of pet products grew 2.1% like for like, mainly owing to Zylkène^{®1}. The Livestock business decreased by 2.0% during first half 2013.

The Asia/Pacific region and the Americas posted like-for-like growth of 3.6% and 0.3% respectively. In a declining European market during Q1 2013, Vétoquinol held up well, with first half sales only 0.9% down.

To date we are not aware of any event since January 1, 2013 having an impact on the Group's financial position as presented in its 2012 financial statements. The Group's strong financial structure was further bolstered by the H1 2013 operating results.

"The integration of Orsco has been effective and the successful launch of the Zylkène[®] range will follow through into the second half of 2013. The Group has a robust financial structure to support its strategy for future growth and we are confident of competing powerfully in the most dynamic markets with a range of well-targeted products," Vétoquinol CEO Matthieu Frechin commented.

¹ A product acquired as part of the Orsco laboratory portfolio, which illustrates the Group's growth strategy in the global products market

Next update: H1 2013 results, August 29, 2013 (after market close)

For immediate release

About Vétoquinol

Vétoquinol is a leading global operator in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and markets veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol has over 1,800 employees.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

emmanuel.dovergne@keima.fr

Media Relations

Alix HERIARD DUBREUIL

Tel.: 01 56 43 44 62

alix.heriard@keima.fr